GlassScriptPhysician profile
Ranjeet Minocha
NPI 1407103492
$11,503.38
in general payments reported to CMS, 2019-2025
22 companies · $1,414 in 2025
The $1,414 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $462 · 2020: $173 · 2021: $636 · 2022: $2,266 · 2023: $1,637 · 2024: $4,915 · 2025: $1,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,377 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,560 · Consulting Fee: $30.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,376.54 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,560.00 |
| Consulting Fee | $30.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $4,165.26 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,283.68 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,211.34 | 2021-2025 | Nucala, Trelegy Ellipta |
| Amgen INC. | $667.19 | 2022-2025 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $351.29 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $327.91 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $232.67 | 2021-2024 | Dupixent |
| Biocryst US Sales Co., LLC | $191.57 | 2022-2025 | Orladeyo |
| Genentech USA, INC. | $155.97 | 2019-2024 | Xolair |
| Pfizer INC. | $151.06 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $135.44 | 2021-2025 | Cuvitru |
| Leo Pharma INC. | $129.50 | 2023 | Adbry |
| Ethicon INC. | $119.36 | 2021 | |
| Genentech, INC. | $112.52 | 2022 | |
| Sanofi-Aventis U.S. LLC | $74.75 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $48.29 | 2024 | |
| Adma Biomanufacturing LLC | $30.23 | 2025 | |
| Jubilant Hollisterstier LLC | $25.24 | 2022 | |
| Kaleo, INC. | $23.52 | 2024 | Auvi-Q |
| Alk-Abello, INC | $23.07 | 2023 | Grastek, Ragwitek, Odactra |
| Grifols USA, LLC | $22.04 | 2024 | Xembify |
| Merck Sharp & Dohme LLC | $21.48 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ranjeet Minocha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.